Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Chiome Bioscience's Debt-to-EBITDA or its related term are showing as below:
TSE:4583'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.28 Med: -0.14 Max: -0.01
Current: -0.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of Chiome Bioscience was -0.01. The lowest was -0.28. And the median was -0.14.
TSE:4583's Debt-to-EBITDA is ranked worse than 100% of 305
companies
in the Biotechnology industry
Industry Median: 1.33
vs TSE:4583: -0.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Chiome Bioscience Debt-to-EBITDA Related Terms
Chiome Bioscience Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Chiome Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Chiome Bioscience (TSE:4583) has a Debt-to-EBITDA of -0.37 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chiome Bioscience. According to the industry distribution chart, Chiome Bioscience ranks #999999 out of 305 companies in the Biotechnology industry.
Is Chiome Bioscience's Debt-to-EBITDA too high?
Chiome Bioscience's current Debt-to-EBITDA is -0.37. Based on the distribution chart, Chiome Bioscience ranks #999999 out of 305 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chiome Bioscience has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #999999 out of 305 companies for Debt-to-EBITDA. This places Chiome Bioscience in the lower half of its industry. The industry median Debt-to-EBITDA is 1.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.33, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chiome Bioscience. For the Biotechnology industry, the median Debt-to-EBITDA is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Debt-to-EBITDA is -0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Fairly Valued. The stock's GF Value™ is 円83.58, compared to a current price of 円85.00 — trading 1.7% above its estimated fair value. The current Debt-to-EBITDA is -0.37. Chiome Bioscience's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Debt-to-EBITDA is -0.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued.
The current stock price of 円85.00 is trading 1.7% above its estimated GF Value™ of 円83.58.
GuruFocus considers Chiome Bioscience to be Fairly Valued.
Key valuation signals for TSE:4583:
Debt-to-EBITDA: -0.37
GF Value™: 円83.58 vs. price of 円85.00 (1.7% above fair value)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
52GF Score
Get the complete analysis for TSE:4583
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
